Category: Cardiac Implants
An new study shows that transcatheter aortic valve-in-valve implantation may be an important option for a growing population of patients with deteriorating bioprosthetic implants, but outcomes depend strongly on how the previous valve is failed.
New research released this week provides more support for the use of transcatheter aortic valve-in-valve (VIV) implantation as a means of replacing previously implanted valves that have deteriorated over time.
Abbott's MitraClip implant reduces mitral regurgitation and improves quality of life at 1 year in high-risk patients, according to new study results from the Everest II clinical trial.
High-risk patients with mitral regurgitation reduced their symptoms and reported better quality of life after treatment with Abbott's (NYSE:ABT) MitraClip implant, according to newly published results from the Everest II High Risk Registry.
Massachusetts-based DC Devices closed a $34 million Series D funding round in supports of its transcatheter InterAtrial Shunt Device.
Bay State startup DC Device announced the successful close of a $34 million Series D financing round, hoping to use the funds to advance clinical evaluation of its InterAtrial Shunt Device.
The company aims to market the world's 1st minimally invasive device for treating diastolic heart failure, a market worth a potential $5 billion globally, according to a DC Device press release.
Medtech titan Boston Scientific finally unveils the full results from its PREVAIL study, which was the subject of controversy at last year's ACC conference.
Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.
Mitralign adds another $8 million to its coffers a few months after closing enrollment on a clinical trial of its mitral valve repair device.
Mitralign added more than $8 million to its coffers in an equity funding round, after closing enrollment of a clinical trial for its namesake mitral valve repair device in April.
The Mitralign system is designed to deliver via catheter at least 1 pair of anchors that, when cinched together, help restore the heart's mitral valve to its natural shape in patients with functional mitral regurgitation, according to a press release.
Medtronic unveils early results from the 1st patients implanted with the pill-sized Micra pacemaker and Sorin shows that its 'SafeR' mode of pacing prevents unnecessary shocks.
The FDA wants to convene another advisory panel on Boston Scientific's Watchman anti-stroke heart repair device, CFO Dan Brennan told investors today in Boston, saying the development pushes the approval timeline into 2015.